Company Description
Exxel Pharma Inc. is a biopharmaceutical company focused on developing novel therapeutics for the treatment of neuronal hypersensitivity disorders.
We are developing EX937, our lead product candidate, for refractory chronic cough (RCC) and other hypersensitivity disorders that share the pathophysiology of hypersensitized sensory neurons.
Investigational New Drug enabling studies supporting our early clinical development program (ERCP) have been completed and we target the first-in-human (FIH) dosing in 2026, pending capitalization and completion of drug product manufacturing.
Exxel Pharma plans to execute the ERCP in Australia, primarily for two reasons, their decentralized regulatory system, which makes early clinical development very effective, and the compelling financial incentives that exist for early clinical development.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Soren Mogelsvang |
Contact Details
Address: 12635 E. Montview Blvd, Suite 134 Aurora, CO 80045 United States | |
| Phone | 908-824-0775 |
| Website | exxelpharma.com |
Stock Details
| Ticker Symbol | EXXL |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2046638 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Soren Mogelsvang | President and CEO, Director |
| Daniele Piomelli | Chief Scientific Officer |
| Robert Dickey IV | Chief Financial Officer |
| Guy Yachin | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 20, 2026 | FWP | Free Writing Prospectus |
| Feb 13, 2026 | FWP | Free Writing Prospectus |
| Feb 2, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 14, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 19, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 2, 2024 | D | Notice of Exempt Offering of Securities |